Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Quisque mi est, blandit sed maximus
Original price was: $63.00.$57.00Current price is: $57.00.Add to cartDuis feugiat sapien et augue dignissim porta. Nullam magna velit, laoreet porta vestibulum nec, auctor sed dui. Integer ac sodales enim. Quisque magna est, mollis euismod nibh in, elementum congue orci. Cras viverra, elit vitae iaculis efficitur, turpis urna sodales eros, vel finibus lacus elit sit amet dolor. Praesent at erat in purus pretium laoreet.
-
Quick View
Donec ullamcorper turpis
$45.00Add to cartAliquam porttitor mattis erat, a eleifend lorem tempor ut. Donec erat lacus, ultricies at dolor sed, accumsan sollicitudin libero. Praesent pellentesque sed odio et fringilla. Donec a semper metus. Nulla mollis sodales sem vitae congue. Donec laoreet nunc sed metus pretium volutpat. Nunc quis feugiat elit.
-
Quick View
Fusce nec diam et dolor
$45.00Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Aliquam id quam elementum arcu eleifend
$44.00Add to cartAenean bibendum posuere neque, quis hendrerit libero ultrices lacinia. Vestibulum venenatis elit non bibendum pulvinar. In luctus urna sapien, posuere fermentum nunc tempus eget. Fusce hendrerit nec diam quis ornare. Duis auctor, libero in efficitur finibus, purus diam maximus est, et rhoncus sapien justo nec sem
Reviews
There are no reviews yet.